AR104716A1 - Agonistas de triazol del receptor apj - Google Patents

Agonistas de triazol del receptor apj

Info

Publication number
AR104716A1
AR104716A1 ARP160101478A ARP160101478A AR104716A1 AR 104716 A1 AR104716 A1 AR 104716A1 AR P160101478 A ARP160101478 A AR P160101478A AR P160101478 A ARP160101478 A AR P160101478A AR 104716 A1 AR104716 A1 AR 104716A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
perhaloalkyl
haloalkyl
heterocyclyl
Prior art date
Application number
ARP160101478A
Other languages
English (en)
Inventor
Yeh Wen
Chen - Yang Kevin
Wang Xiaodong
Swaminath Gayathri
Pattaropong Vatee
H Olson Steven
Nishimura Nobuko
T Mihalic Jeffrey
C Medina Julio
R Mgee Lawrence
Ma Zhihua
Lai Su
John Jen - Kopecky David
Yusuf Khakoo Aarif
Kayser Frank
R Kaller Matthew
C Judd Ted
Houze Jonathan
B Horne Daniel
Anne Heath Julie
J Hedley Simon
Fu Zice
P Farrell Robert
Du Xiaohui
John Dransfield Paul
Deignan Jeffrey
V Debenedetto Mikkel
V Connors Richard
C Cheng Alan
Chen Yinhong
Chen Xiaoqi
Chen Ning
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR104716A1 publication Critical patent/AR104716A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se describen compuestos de la fórmula (1) y fórmula (2), sal farmacéuticamente aceptable del mismo, estereoisómeros de cualquiera de los anteriores, o mezclas de los mismos que son agonistas del receptor APJ y tienen uso en tratar afecciones cardiovasculares y otras. Reivindicación 1: Un compuesto de la fórmula (1) o la fórmula (2), o una sal farmacéuticamente aceptable del mismo, un tautómero del mismo, una sal farmacéuticamente aceptable del tautómero, un estereoisómero de cualquiera de los anteriores, o una mezcla de los mismos, caracterizado porque: R¹ es un piridilo, piridonilo, o piridina N-óxido no sustituido, o es un piridilo, piridonilo, o piridina N-óxido sustituido con 1, 2, 3, ó 4 sustituyentes R¹ᵃ; R¹ᵃ en cada caso es seleccionado independientemente de -F, -Cl, -Br, -I, -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -perhaloalquilo C₁₋₆, -OH, -O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆), -alquenilo C₁₋₆, -O-(alquilo C₁₋₆)-OH, -O-(alquilo C₁₋₆)-O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆)-OH, -O-(haloalquilo C₁₋₆)-O-(alquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆)-OH, -O-(perhaloalquilo C₁₋₆)-O-(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, -C(=O)-(alquilo C₁₋₆), -C(=O)OH, -C(=O)-O-(alquilo C₁₋₆), -C(=O)NH₂, -C(=O)NH(alquilo C₁₋₆), -C(=O)N(alquilo C₁₋₆)₂, fenilo, -C(=O)-(heterociclilo), o un grupo heterociclilo, en donde el grupo heterociclilo del -C(=O)-(heterociclilo) o grupo heterociclilo es un anillo de 3 hasta 7 miembros que contiene 1, 2, ó 3 heteroátomos seleccionados de N, O, o S; R² se selecciona de -H, o alquilo C₁₋₄ o está ausente en los compuestos de la fórmula (2); R³ se selecciona de un alquilo C₁₋₁₀ no sustituido, un alquilo C₁₋₁₀ sustituido con 1, 2 ó 3 sustituyentes R³ᵃ, un grupo de la fórmula -(CR³ᵇR³ᶜ)-Q, un grupo de la fórmula -NH-(CR³ᵇR³ᶜ)-Q, un grupo de la fórmula -(CR³ᵇR³ᶜ)-C(=O)-Q, un grupo de la fórmula -(CR³ᵈR³ᵉ)-(CR³ᶠR³ᵍ)-Q, un grupo de la fórmula -(CR³ᵇ=CR³ᶜ)-Q, o un grupo de la fórmula -(heterociclilo)-Q, en donde el heterociclilo del -(heterociclilo)-Q tiene 5 hasta 7 miembros en el anillo de los cuales 1, 2, ó 3 son heteroátomos seleccionados de N, O, o S y está no sustituido o está sustituido con 1, 2, ó 3 sustituyentes R³ʰ; R³ᵃ en cada caso es seleccionado independientemente de -F, -Cl, -CN, -OH, -O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆), -O-(alquilo C₁₋₆)-OH, -O-(alquilo C₁₋₆)-O-(alquilo C₁₋₆), alquenilo C₂₋₆, alquinilo C₂₋₆, -NH₂, -NH(alquilo C₁₋₆), o -N(alquilo C₁₋₆)₂; R³ᵇ y R³ᶜ son seleccionados independientemente de -H, -F, -Cl, -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -perhaloalquilo C₁₋₆, -OH, -O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆), -O-(alquilo C₁₋₆)-OH, -O-(alquilo C₁₋₆)-O-(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), o -N(alquilo C₁₋₆)₂; R³ᵈ y R³ᵉ son seleccionados independientemente de -H, -F, -Cl, -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -perhaloalquilo C₁₋₆, -OH, -O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆), -O-(alquilo C₁₋₆)-OH, -O-(alquilo C₁₋₆)-O-(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), o -N(alquilo C₁₋₆)₂; R³ᶠ y R³ᵍ son seleccionados independientemente de -H, -F, -Cl, -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -perhaloalquilo C₁₋₆, -OH, -O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆), -O-(alquilo C₁₋₆)-OH, -O-(alquilo C₁₋₆)-O-(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), o -N(alquilo C₁₋₆)₂; R³ʰ en cada caso es seleccionado independientemente de -F, -Cl, -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -perhaloalquilo C₁₋₆, -OH, -O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆), -O-(alquilo C₁₋₆)-OH, -O-(alquilo C₁₋₆)-O-(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, u oxo; Q es un grupo arilo C₆₋₁₀ monocíclico o bicíclico, un grupo heteroarilo monocíclico o bicíclico con 5 hasta 10 miembros en el anillo que contiene 1, 2, ó 3 heteroátomos seleccionados de N, O, o S, un grupo cicloalquilo C₃₋₈, o un grupo heterociclilo de 3 hasta 7 miembros que contiene 1, 2, ó 3 heteroátomos seleccionados de N, O, o S, en donde el grupo arilo C₆₋₁₀, el grupo heteroarilo, el grupo cicloalquilo, y el grupo heterociclilo están no sustituidos o están sustituidos con 1, 2, 3, ó 4 sustituyente RQ; RQ en cada caso es seleccionado independientemente de -F, -Cl, -Br, -I, -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -perhaloalquilo C₁₋₆, -alquenilo C₂₋₆, -alquinilo C₂₋₆, -OH, -O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, -C(=O)-(alquilo C₁₋₆), -C(=O)OH, -C(=O)-O-(alquilo C₁₋₆), -C(=O)NH₂, -C(=O)NH(alquilo C₁₋₆), C(=O)N (alquilo C₁₋₆)₂, -S(=O)₂-(alquilo C₁₋₆), fenilo, o un grupo heteroarilo, y el grupo heterociclilo Q puede estar sustituido con 1 oxo sustituyente RQ; R⁴ se selecciona de un grupo arilo C₆₋₁₀ monocíclico o bicíclico, un grupo heteroarilo monocíclico o bicíclico con 5 hasta 10 miembros en el anillo que contiene 1, 2, ó 3 heteroátomos seleccionados independientemente de N, O, o S, o un grupo heterociclilo monocíclico o bicíclico con 5 hasta 10 miembros en el anillo que contiene 1, 2, 3, ó 4 heteroátomos seleccionados independientemente de N, O, o S, en donde el grupo arilo C₆₋₁₀, el grupo heteroarilo, o el grupo heterociclilo están no sustituidos o están sustituidos con 1, 2, ó 3 sustituyentes R⁴ᵃ; R⁴ᵃ en cada caso es seleccionado independientemente de -F, -Cl, -Br, -I, -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -perhaloalquilo C₁₋₆, -OH, -O-(alquilo C₁₋₆), -O-(haloalquilo C₁₋₆), -O-(perhaloalquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, -C(=O)-(alquilo C₁₋₆), -C(=O)OH, -C(=O)-O-(alquilo C₁₋₆), C(=O)NH₂, -C(=O)NH(alquilo C₁₋₆), o -C(=O)N(alquilo C₁₋₆)₂, y el grupo heterociclilo R⁴ puede estar sustituido además con 1 oxo sustituyente; y en donde además: si R⁴ es un anillo fenilo no sustituido o sustituido y R³ es un grupo de la fórmula -(CR³ᵇ=CR³ᶜ)-Q, entonces al menos uno de los siguientes es cierto: a) R⁴ es sustituido con al menos un grupo -O-(alquilo C₁₋₆); b) Q no es un oxadiazol; c) R³ᵇ no es -H; d) R³ᶜ no es -H; e) R¹ no es un grupo 2-piridilo; o f) R⁴ es sustituido con dos o más grupos -O-(alquilo C₁₋₆).
ARP160101478A 2015-05-20 2016-05-20 Agonistas de triazol del receptor apj AR104716A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164106P 2015-05-20 2015-05-20

Publications (1)

Publication Number Publication Date
AR104716A1 true AR104716A1 (es) 2017-08-09

Family

ID=56134572

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101478A AR104716A1 (es) 2015-05-20 2016-05-20 Agonistas de triazol del receptor apj

Country Status (38)

Country Link
US (10) US9573936B2 (es)
EP (1) EP3300500B9 (es)
JP (3) JP6356364B1 (es)
KR (1) KR102653667B1 (es)
CN (1) CN108137545B (es)
AR (1) AR104716A1 (es)
AU (1) AU2016263564B2 (es)
BR (1) BR112017024618B1 (es)
CA (1) CA2985542C (es)
CL (1) CL2017002922A1 (es)
CO (1) CO2017012991A2 (es)
CY (1) CY1123451T1 (es)
DK (1) DK3300500T3 (es)
EA (1) EA034776B1 (es)
ES (1) ES2791315T3 (es)
HK (1) HK1253366A1 (es)
HR (1) HRP20200690T1 (es)
HU (1) HUE050317T2 (es)
IL (1) IL255459A (es)
JO (1) JO3653B1 (es)
LT (1) LT3300500T (es)
MA (1) MA42145B1 (es)
ME (1) ME03733B (es)
MX (1) MX2017014818A (es)
MY (1) MY193818A (es)
NZ (1) NZ737004A (es)
PE (1) PE20180529A1 (es)
PH (1) PH12017502107A1 (es)
PL (1) PL3300500T3 (es)
PT (1) PT3300500T (es)
RS (1) RS60353B1 (es)
SI (1) SI3300500T1 (es)
TN (1) TN2017000483A1 (es)
TW (1) TWI606039B (es)
UA (1) UA119932C2 (es)
UY (1) UY36684A (es)
WO (1) WO2016187308A1 (es)
ZA (1) ZA201707706B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1143120A (ja) * 1997-07-28 1999-02-16 Ishikawajima Harima Heavy Ind Co Ltd 容器の後処理装置
SI3300500T1 (sl) 2015-05-20 2020-07-31 Amgen Inc. Triazolni agonisti receptorja APJ
AU2016270903B2 (en) 2015-06-03 2020-04-30 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists for use in the treatment of cardiovascular disorders
CN108368087B (zh) 2015-10-14 2022-04-12 百时美施贵宝公司 作为apj激动剂的2，4-二羟基-烟酰胺
WO2017165640A1 (en) 2016-03-24 2017-09-28 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541804A1 (en) 2016-11-16 2019-09-25 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3668601A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN108795853B (zh) * 2018-05-28 2021-08-24 天津博雅秀岩生物技术有限公司 制备犬胎膜间充质干细胞的方法和犬胎膜间充质干细胞
CN108728408B (zh) * 2018-05-28 2021-08-24 天津博雅秀岩生物技术有限公司 犬胎膜间充质干细胞及制备方法和使用的培养基
WO2022216871A1 (en) * 2021-04-06 2022-10-13 BioAge Labs, Inc. Apelin receptor modulators for treating age-related muscle conditions
WO2024072907A1 (en) 2022-09-27 2024-04-04 BioAge Labs, Inc. Apelin receptor agonists for treating muscle conditions
CN117417325A (zh) * 2023-12-19 2024-01-19 药康众拓(北京)医药科技有限公司 氘代1,2,4-三唑类Apelin受体激动剂药物及用途

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4681943A (en) * 1984-11-30 1987-07-21 The Dow Chemical Company 1-acyl-1-(2-pyridinyl)semicarbazides
JPS62149673A (ja) * 1985-09-05 1987-07-03 Sumitomo Chem Co Ltd ピリジン誘導体、その製造法およびそれを有効成分とする植物病害防除剤
DE3825867A1 (de) 1988-03-04 1989-09-14 Bayer Ag Heterocyclisch substituierte sulfonylaminoazole und ihre verwendung als herbizide
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
DE3928605A1 (de) 1989-08-30 1991-03-07 Bayer Ag Substituierte sulfonylaminoazole
CA2075639A1 (en) 1990-02-13 1991-08-14 William J. Greenlee Triazole angiotensin ii antagonists incorporating a substituted benzyl element
JPH0511439A (ja) 1990-09-13 1993-01-22 Fuji Photo Film Co Ltd 光重合性組成物
DE4035141A1 (de) 1990-11-06 1992-05-07 Bayer Ag Substituierte sulfonylaminotriazolylpyrimidine
CZ283018B6 (cs) 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
SE9103397D0 (sv) 1991-11-18 1991-11-18 Kabi Pharmacia Ab Nya substituerade salicylsyror
JP3217846B2 (ja) * 1992-03-04 2001-10-15 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫剤
CA2129146A1 (en) 1992-03-13 1993-09-16 Victor Giulio Matassa Imidazole, triazole and tetrazole derivatives
US5411839A (en) 1993-01-15 1995-05-02 Eastman Kodak Company Image formation in color reversal materials using strong inhibitors
BR9607017A (pt) 1995-02-03 1997-10-28 Upjohn Co Composto e uso do mesmo
US5563026A (en) 1995-04-28 1996-10-08 Eastman Kodak Company Color negative element having improved green record printer compatibility
DE19725450A1 (de) 1997-06-16 1998-12-17 Hoechst Schering Agrevo Gmbh 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
JP3788676B2 (ja) 1997-11-11 2006-06-21 富士写真フイルム株式会社 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子
US6069141A (en) 1998-02-13 2000-05-30 Pharmacia & Upjohn Company Substituted aminophenyl isoxazoline derivatives useful as antimicrobials
CA2318762A1 (en) 1998-02-25 1999-09-02 Richard Charles Thomas Substituted aminomethyl isoxazoline derivatives useful as antimicrobials
WO2001017995A1 (en) 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1265921B1 (en) 2000-03-16 2007-05-23 Genesoft, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
CA2403447A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Peptide derivative
RU2002133666A (ru) 2000-05-19 2007-05-10 Мерк Патент ГмбХ (DE) Производные триазола
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
AU2002232919A1 (en) 2000-12-29 2002-07-16 Alteon, Inc. Method for treating fibrotic diseases or other indications
US6962936B2 (en) * 2001-04-27 2005-11-08 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6790846B2 (en) 2001-05-24 2004-09-14 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
JP2003005356A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
JP2003321456A (ja) 2002-04-30 2003-11-11 Fuji Photo Film Co Ltd ５−アミノ−４−含窒素芳香族ヘテロ環置換ピラゾール類の製造方法
JP4413781B2 (ja) 2002-08-23 2010-02-10 アーディア・バイオサイエンシーズ・インコーポレイテッド 非ヌクレオシド逆転写酵素インヒビター
US7084145B2 (en) 2002-10-25 2006-08-01 Pfizer Inc. Triazole compounds useful in therapy
EP1581222A2 (en) 2003-01-02 2005-10-05 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr;
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
WO2004078923A2 (en) 2003-02-28 2004-09-16 Plexxikon, Inc. Pyk2 crystal structure and uses
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
EP1664052B1 (en) 2003-08-15 2009-02-18 AstraZeneca AB Fused heterocycles as inhibitors of glutamate racemase (muri)
EP1677786A1 (en) 2003-10-18 2006-07-12 Bayer HealthCare AG 5-substituted 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
WO2005073193A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7297168B2 (en) 2004-02-02 2007-11-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
JP2007530589A (ja) 2004-03-26 2007-11-01 アンフォラ ディスカバリー コーポレーション 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用
EP1773807A2 (en) 2004-06-14 2007-04-18 Takeda San Diego, Inc. Kinase inhibitors
US7399317B2 (en) 2004-08-26 2008-07-15 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
CA2580409C (en) 2004-09-16 2013-08-13 Astellas Pharma Inc. Triazole derivative or salt thereof
EP2298748B1 (en) 2004-11-18 2016-07-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20060156480A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
JP5044730B2 (ja) 2005-03-09 2012-10-10 日本化薬株式会社 新規なｈｓｐ９０阻害剤
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
CA2602383A1 (en) 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CA2603701A1 (en) 2005-04-06 2006-10-19 Banyu Pharmaceutical Co., Ltd. 1,4-substituted piperazine derivative
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
WO2007021941A2 (en) 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
WO2007022947A2 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP2013180A1 (en) 2006-04-19 2009-01-14 Laboratoires Serono SA Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors
TW200806637A (en) 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity
JP5441691B2 (ja) 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
TW200800260A (en) 2006-05-25 2008-01-01 Synta Pharmaceuticals Corp Method for treating proliferative disorders associated with protooncogene products
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2653336C (en) 2006-05-25 2014-10-28 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
AU2012200157B2 (en) 2006-05-25 2014-08-21 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
WO2008005457A2 (en) 2006-06-30 2008-01-10 Sunesis Pharmaceuticals Pyridinonyl pdk1 inhibitors
CN101511800B (zh) 2006-07-14 2013-02-27 坎莫森特里克斯公司 三唑基苯基苯磺酰胺
US7718683B2 (en) 2006-07-14 2010-05-18 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
WO2008021364A2 (en) 2006-08-17 2008-02-21 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20110046125A1 (en) 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
US7909187B2 (en) 2007-02-20 2011-03-22 Lonzell Montgomery Modular baby bottle system
US8993608B2 (en) 2007-03-12 2015-03-31 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase II
WO2008153730A2 (en) 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
EP2188271B1 (en) 2007-07-17 2017-01-11 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents
CA2695995C (en) 2007-08-13 2015-09-29 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009075890A2 (en) 2007-12-12 2009-06-18 Synta Pharmaceuticals Corp. Method for synthesis of triazole compounds that modulate hsp90 activity
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
MX338530B (es) 2008-06-03 2016-04-21 Siga Technologies Inc Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
AU2009266956B2 (en) 2008-07-01 2014-03-20 Genentech, Inc. Bicyclic heterocycles as MEK kinase inhibitors
CN102137843A (zh) 2008-07-01 2011-07-27 健泰科生物技术公司 作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
US20100031237A1 (en) 2008-08-01 2010-02-04 International Business Machines Corporation Methods for Detecting Inter-Module Dependencies
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
DE102008059702A1 (de) 2008-12-01 2010-06-02 Byk-Chemie Gmbh Verfahren zur Herstellung rheologisch wirksamer Harnstoffurethane in organischen Salzen
CA2764339A1 (en) 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors
EP2440050A4 (en) 2009-06-08 2013-04-03 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
US8846739B2 (en) 2009-12-11 2014-09-30 Exelixis Patent Company Llc TGR5 agonists
KR102113960B1 (ko) 2010-03-30 2020-05-21 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011133521A2 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US20130172333A1 (en) 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
BR112013000925A2 (pt) 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
WO2012021778A2 (en) 2010-08-12 2012-02-16 The Regents Of The University Of California Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition
WO2012027482A2 (en) * 2010-08-24 2012-03-01 Georgetown University Compounds, compositions and methods related to ppar antagonists
JP5517890B2 (ja) * 2010-11-15 2014-06-11 サンデン株式会社 ショーケース及び照明モジュール
RU2013128448A (ru) * 2010-12-08 2015-01-20 Осло Юниверсити Хоспитал Хф Производные триазола в качестве ингибиторов сигнального пути wnt
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
EP2739286A4 (en) 2011-08-04 2015-06-03 Lumena Pharmaceuticals Inc INHIBITORS OF RECYCLING OF BILIARY ACID IN THE TREATMENT OF PANCREAS
US9593109B2 (en) 2011-08-26 2017-03-14 Cymabay Therapeutics, Inc. Bicyclic agonists of GPR131 and uses thereof
PL2771003T3 (pl) 2011-10-28 2017-10-31 Lumena Pharmaceuticals Llc Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
EP2776025A1 (en) 2011-11-02 2014-09-17 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014533299A (ja) 2011-11-14 2014-12-11 シンタ ファーマシューティカルズ コーポレーション Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法
EP2802596A1 (en) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
AU2013239663A1 (en) 2012-03-28 2014-10-09 Synta Pharmaceuticals Corp. Triazole derivatives as HSP90 inhibitors
CN110664816A (zh) 2012-06-07 2020-01-10 佐治亚州立大学研究基金会公司 Seca抑制剂以及其制备和使用方法
US20140005181A1 (en) * 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
HUE031733T2 (en) 2012-09-21 2017-07-28 Sanofi Sa Benzimidazole carboxylic acid amide derivatives for the treatment of metabolic or cardiovascular diseases
EP2935311B1 (en) 2012-12-20 2021-03-31 Amgen Inc. Apj receptor agonists and uses thereof
AU2014237312B2 (en) 2013-03-15 2019-03-28 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
UY35517A (es) 2013-04-04 2014-10-31 Mabxience S A Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína
US9957289B2 (en) 2013-05-30 2018-05-01 Washington University Compounds and methods for treating bacterial infections
EP3120142B1 (en) 2014-03-20 2018-12-19 Centre National de la Recherche Scientifique (C.N.R.S.) Compounds inhibiting apelin / apj / gp130 signaling for use for treating cancer by inhibiting cancer stem cells
CN106459160B (zh) 2014-04-24 2022-03-29 南洋理工大学 Asx特异性蛋白质连接酶
US10570128B2 (en) * 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
RU2705800C2 (ru) 2014-06-06 2019-11-12 Рисерч Трайэнгл Инститьют Агонисты рецептора апелина (apj) и их применение
US20160058705A1 (en) 2014-08-28 2016-03-03 Jayakumar Rajadas Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin
SI3300500T1 (sl) 2015-05-20 2020-07-31 Amgen Inc. Triazolni agonisti receptorja APJ
AU2016270903B2 (en) 2015-06-03 2020-04-30 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists for use in the treatment of cardiovascular disorders
EP3115826A1 (de) 2015-07-06 2017-01-11 Trumpf Laser Marking Systems AG Vorrichtung zur ablenkung eines laserstrahls
WO2017010058A1 (ja) 2015-07-14 2017-01-19 パナソニックＩｐマネジメント株式会社 識別媒体認識装置および識別媒体認識方法
CN108368087B (zh) 2015-10-14 2022-04-12 百时美施贵宝公司 作为apj激动剂的2，4-二羟基-烟酰胺
US10626096B2 (en) 2015-11-24 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Azole derivatives as apelin receptor agonist
MX2018006217A (es) 2015-12-04 2018-08-01 Squibb Bristol Myers Co Agonistas del receptor de apelina y metodos de uso.
WO2017100558A1 (en) 2015-12-09 2017-06-15 Research Triangle Institute Improved apelin receptor (apj) agonists and uses thereof
US9988369B2 (en) * 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor

Also Published As

Publication number Publication date
JP6055150B1 (ja) 2016-12-27
ME03733B (me) 2021-01-20
PE20180529A1 (es) 2018-03-19
UA119932C2 (uk) 2019-08-27
EP3300500A1 (en) 2018-04-04
US20170044131A1 (en) 2017-02-16
WO2016187308A1 (en) 2016-11-24
US10058550B2 (en) 2018-08-28
US9745286B2 (en) 2017-08-29
US20170035744A1 (en) 2017-02-09
EA034776B1 (ru) 2020-03-19
US10221162B2 (en) 2019-03-05
US9751864B2 (en) 2017-09-05
US9656998B2 (en) 2017-05-23
US20180319773A1 (en) 2018-11-08
NZ737004A (en) 2022-10-28
LT3300500T (lt) 2020-05-25
US20170037026A1 (en) 2017-02-09
SI3300500T1 (sl) 2020-07-31
MA42145A (fr) 2018-04-04
JP6356364B1 (ja) 2018-07-11
ZA201707706B (en) 2022-11-30
JP2017036260A (ja) 2017-02-16
TWI606039B (zh) 2017-11-21
CN108137545A (zh) 2018-06-08
MA42145B1 (fr) 2020-05-29
IL255459A (en) 2018-01-31
HRP20200690T1 (hr) 2020-07-24
JP2017061546A (ja) 2017-03-30
RS60353B1 (sr) 2020-07-31
MX2017014818A (es) 2018-02-09
HK1253366A1 (zh) 2019-06-14
PL3300500T3 (pl) 2020-08-24
CA2985542C (en) 2023-10-10
CL2017002922A1 (es) 2018-03-16
TN2017000483A1 (en) 2019-04-12
UY36684A (es) 2016-12-30
CA2985542A1 (en) 2016-11-24
US9656997B2 (en) 2017-05-23
EA201792536A1 (ru) 2018-10-31
CN108137545B (zh) 2020-09-22
ES2791315T3 (es) 2020-11-03
MY193818A (en) 2022-10-27
EP3300500B9 (en) 2021-01-13
US20160340336A1 (en) 2016-11-24
US10344016B2 (en) 2019-07-09
US20170042897A1 (en) 2017-02-16
TW201706248A (zh) 2017-02-16
BR112017024618B1 (pt) 2023-03-14
CO2017012991A2 (es) 2018-03-28
US20190100510A1 (en) 2019-04-04
US9845310B2 (en) 2017-12-19
JP2018524281A (ja) 2018-08-30
US20170042871A1 (en) 2017-02-16
US20170042872A1 (en) 2017-02-16
BR112017024618A2 (pt) 2018-11-13
KR102653667B1 (ko) 2024-04-03
US20170281625A1 (en) 2017-10-05
PH12017502107A1 (en) 2018-04-02
AU2016263564B2 (en) 2019-12-05
US9573936B2 (en) 2017-02-21
CY1123451T1 (el) 2022-03-24
EP3300500B1 (en) 2020-02-26
PT3300500T (pt) 2020-05-19
HUE050317T2 (hu) 2020-11-30
JO3653B1 (ar) 2020-08-27
JP6130964B2 (ja) 2017-05-17
US9868721B2 (en) 2018-01-16
KR20180011164A (ko) 2018-01-31
AU2016263564A1 (en) 2017-11-30
DK3300500T3 (da) 2020-05-18

Similar Documents

Publication Publication Date Title
AR104716A1 (es) Agonistas de triazol del receptor apj
AR106948A1 (es) Agonistas del receptor de apelina y método de uso
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR109805A1 (es) Derivados de oxadiazol microbiocidas
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR110922A1 (es) Compuestos inhibidores del vih
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
AR095312A1 (es) Compuestos de biarilamida como inhibidores de cinasa
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR103397A1 (es) Oxoborazoles microbicidas
AR104837A1 (es) Compuestos heterocíclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de nmda nr2b
AR113811A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
AR102825A1 (es) Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre
AR109651A1 (es) Compuestos de piridina y pirazina como inhibidores de ripk2
AR089887A1 (es) Compuestos fungicidas de pirimidina
AR091534A1 (es) Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco
AR090335A1 (es) Compuestos funguicidas de pirimidina